Kymera Therapeutics

Kymera Therapeutics Announces Leadership Transitions

Kymera Co-founder and CSO Nello Mainolfi, PhD, has been appointed President of the company as former President and CEO Laurent Audoly, PhD, has decided to pursue new entrepreneurial opportunities. Kymera Therapeutics also announced that health care financial services veteran Bruce Jacobs joins as Chief Financial Officer to direct financial operations and investor relations.

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

Cambridge, Mass. (June 19, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data demonstrating its first-in-class oral IRAK4 protein degraders cause tumor regression in MYD88-mutant B cell lymphoma. Data will be shared during an oral presentation at the 15th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Thursday, June 20 at 5:45 PM CEST.

Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases

BOSTON, MA and CAMBRIDGE, MA – May 15, 2019 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Kymera Therapeutics today announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to accelerate the development of first-in-class medicines for people with serious diseases.

Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant Lymphoma at Late-Breaking Session of the American Association for Cancer Research Annual Meeting

Cambridge, Mass. (March 29, 2019) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma. Data will be presented  in a late-breaking research session at the American Association for Cancer Research Annual Meeting on April 3 from 8 a.m. – 12 p.m. (Poster #18, Session: Experimental and Molecular Therapeutics 2). The study showed that KYM-001 led to highly selective degradation of IRAK4 and tumor regression upon oral dosing, both alone and in combination with BTK inhibition.

Kymera Therapeutics Announces Expansion of Scientific Advisory Board to Advance Pre-Clinical Molecules Toward the Clinic

Cambridge, Mass. (Dec. 18, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced the expansion of its Scientific Advisory Board (SAB) to support development of the company’s Pegasus platform and advancement of its small molecule-based protein degrader therapeutics into the clinic. The board is comprised of world-class scientists and clinicians, including experts in proteomics, human genetics, chemistry, E3 ligase biology and translational and clinical research.

Kymera Therapeutics Presents First Validation of IRAK4 Protein Degraders in MYD88-Mutant Lymphoma

Cambridge, Mass. (Dec. 3, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, today announced research demonstrating preclinical activity of the company’s first-in-class heterobifunctional small molecules to specifically degrade IRAK4 in MYD88 (myeloid differentiation primary response 88)-mutant lymphoma. Data were presented at the 60th Annual Meeting of the American Society of Hematology (ASH) in San Diego (Poster #2593, Session 625, Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II).

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

Cambridge, Mass. (Nov. 13, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today that it has completed a $65 million Series B financing.  The financing will support the advancement of its lead asset into clinical development, and to progress its therapeutic pipeline in oncology and immunology.  The financing was co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures with participation by MRL Ventures Fund, Sanofi Ventures, Hatteras Venture Partners, and Aju IB Investment, in addition to Kymera’s Series A investors. The company also announced Wei Li, PhD, of 6 Dimensions Capital, Andrew Hedin of Bessemer Venture Partners, and Elaine Jones, PhD, of Pfizer Ventures, will join Kymera Therapeutics’ Board of Directors.

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

Cambridge, Mass. (September 20, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of Jared Gollob, MD, to the role of Chief Medical Officer.  Formerly Vice President of Clinical Development and Global Vice President of Medical Affairs at Alnylam Pharmaceuticals, Dr. Gollob joins to build and lead Kymera’s clinical strategy and organization.

Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors

Cambridge, Mass. (April 23, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients has announced that Joanna Horobin, M.B., Ch.B, Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals has joined the company’s Board of Directors and Scientific Advisory Board.

Kymera Therapeutics Announces Discovery Collaboration with GSK to Advance New Treatment Modality

Cambridge, Mass. (April 4, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced it has entered into a two-year discovery collaboration agreement with GSK, a science-led global healthcare company that is leveraging innovations in small molecule-based targeted protein degradation and encoded library technologies.